NAD+

What NAD+ is

NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme present in every cell of all known life forms. Structurally, it consists of two nucleotides—nicotinamide (derived from niacin, vitamin B3) and adenine—joined by a phosphate bridge. It exists in two interconvertible forms: the oxidised NAD+ and the reduced NADH, and this redox cycling is central to how cells extract energy from nutrients ^[1][3]. Beyond its role as an electron carrier, NAD+ functions as a direct substrate for several classes of signalling enzymes, including sirtuins (deacetylases regulating stress response and longevity) and poly(ADP-ribose) polymerases (PARPs, which orchestrate DNA repair), making it a regulatory hub rather than a simple fuel molecule ^[2][3].

The scientific story of NAD+ began in 1906 when British biochemists Arthur Harden and William John Young, working at the Lister Institute, observed that adding boiled yeast extract dramatically accelerated alcoholic fermentation in living yeast cells. The active component of that extract—then called 'cozymase'—was later identified as NAD+ ^[5]. In 1929, Harden shared the Nobel Prize in Chemistry for this work. Decades later, in the 1930s, Otto Warburg clarified NAD+'s electron-transfer function in cellular energy generation, and Hans von Euler-Chelpin achieved its purification. By the mid-twentieth century, the coenzyme's involvement in glycolysis, the Krebs cycle, and mitochondrial respiration was established. Modern interest intensified dramatically in the 2000s–2010s when researchers discovered that NAD+ levels decline systemically with aging and that this decline is mechanistically linked to multiple age-related pathologies ^[2][4].

What it is being researched for

1. Aging biology and longevity

One of the most intensively studied aspects of NAD+ is its relationship to the aging process. Research consistently shows that NAD+ levels decrease across multiple tissues as organisms age, and that this decline contributes to nuclear and mitochondrial dysfunction, ultimately giving rise to age-related pathologies ^[1][2]. In animal models, strategies that restore NAD+ pools—principally through precursor supplementation—have been associated with reductions in age-associated phenotypes, including impaired neurovascular coupling, reduced neural stem cell renewal, and cataracts ^[4]. The balance between NAD+ biosynthesis (driven by enzymes such as NAMPT) and its consumption by PARPs and sirtuins is now understood as a key determinant of biological age, and disruption of this balance is implicated in senescence ^[2][3]. A 2026 PRISMA-guided systematic review covering 113 eligible studies (33 human, 80 rodent) found that in rodent models, NAD+ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory, and functional outcomes, though effects varied across models and endpoints ^[6].

2. Cognitive function and neurodegeneration

Declining NAD+ is hypothesised to render the brain less resilient to neurodegenerative diseases, because neuronal mitochondrial dysfunction is especially pronounced in pathological brain aging such as Alzheimer's disease (AD) and vascular cognitive impairment ^[10]. Preclinical research has found that NAD+ precursor supplementation with NMN or NR can reduce amyloid-beta and tau-related pathology in murine AD models, while human studies show that NR increases neuronal NAD+ levels and modulates plasma biomarkers linked to neurodegenerative pathology—including reductions in pTau217—in older adults ^[8][11]. However, human clinical trial results on cognitive outcomes are largely inconclusive: a randomised trial in older adults with mild cognitive impairment found that NR was well tolerated and raised blood NAD+ significantly, yet produced no measurable improvement in cognitive function ^[8]. A 2024 eClinicalMedicine randomised controlled trial in long-COVID patients similarly confirmed effective NAD+ elevation by NR but found no significant cognitive improvement versus placebo ^[12]. Head-to-head comparisons of different precursors and adequately powered, longer-term trials remain an important research gap ^[7].

3. Cardiovascular health

NAD+ is integral to cardiac energy homeostasis: cardiomyocytes have exceptionally high energy demands, and a reduction in cardiac NAD+ content is now associated with mitochondrial dysfunction, increased reactive oxygen species (ROS) production, and cell death ^[9]. Research published in Circulation identified that NAD+ pools decline with normal aging, obesity, and hypertension—all major cardiovascular risk factors—and that NAD+ replenishment in preclinical models extends healthspan, prevents metabolic syndrome, and reduces blood pressure ^[8]. Experimental elevation of NAD+ has also been found to improve atherosclerosis, ischemic cardiomyopathy, and different modalities of heart failure in animal studies ^[8]. In addition, therapeutic elevation of NAD+ levels has been shown to reduce chronic low-grade inflammation, reactivate autophagy and mitochondrial biogenesis, and enhance oxidative metabolism in vascular cells of humans and rodents with vascular disorders ^[9]. Clinical trials in cardiovascular populations are ongoing but remain at early phases ^[8].

4. Metabolic health and insulin sensitivity

NAD+ plays a central role in regulating energy metabolism, and its depletion has been linked to metabolic disorders including obesity and type 2 diabetes. In preclinical models, NAD+ boosting can prevent metabolic syndrome and improve parameters of glucose homeostasis ^[9]. A notable human clinical trial published in Science found that NMN significantly increased muscle insulin sensitivity in overweight or obese postmenopausal women with prediabetes, representing one of the more compelling translational findings in this area ^[8]. A 2022 randomised placebo-controlled trial in healthy overweight or obese adults found that NMN treatment significantly increased blood NAD+, with beneficial shifts in lipid parameters including decreases in total cholesterol and LDL cholesterol in the NMN group versus placebo ^[4]. NAD+ precursors are also being investigated in the context of cardiometabolic disease, with clinical trials in populations ranging from healthy overweight adults to pre-diabetic women ^[6][7].

5. DNA repair and genome integrity

PARP enzymes are the cell's primary orchestrators of DNA strand-break repair, and they consume NAD+ as their obligate substrate, using it to attach poly(ADP-ribose) chains to damaged chromatin and recruit repair machinery ^[3]. Fluctuations in cellular NAD+ therefore directly influence the efficiency of DNA repair, chromatin structure, telomere function, and cell-death pathways ^[5]. Overactivation of PARP—as occurs during severe genotoxic stress—can deplete the cellular NAD+ pool catastrophically, leading to cellular necrosis ^[3]. NAD+ supplementation has been studied in the context of rare DNA repair disorders including Xeroderma pigmentosum (XPA), Cockayne syndrome group B (CSB), and Ataxia-Telangiectasia, where precursor supplementation has been shown to decrease the accumulation of endogenous DNA damage and improve repair capacity in preclinical settings ^[5]. The sirtuin SIRT6 also participates in DNA repair pathways and helps maintain genome stability in an NAD+-dependent manner ^[3].

6. Skin aging and photoprotection

Emerging research is exploring the role of NAD+ in cutaneous aging and protection against ultraviolet (UV)-induced damage. In vitro studies using human fibroblasts have shown that exogenous NAD+ can exert protective effects against both UV-induced photoaging and intrinsic aging, with proposed mechanisms including improved sirtuin activation, autophagy, and mitochondrial functionality ^[10]. NAD+ is also consumed by PARP-1 when UV radiation induces DNA strand breaks in skin cells, and maintaining adequate NAD+ pools may be critical to efficient repair of UV-induced lesions. Research groups have investigated synergistic approaches—for example, combining NAD+ with phytochemical CD38 inhibitors such as quercetin—to extend the half-life of NAD+ in skin tissue and amplify its protective effects ^[10]. This area is at an early preclinical stage and human evidence is very limited.

7. Ischemia-reperfusion injury and tissue protection

NAD+ decline is an important molecular event in ischemic injury. During ischemia and subsequent reperfusion, PARP hyperactivation triggered by oxidative DNA damage can drain cellular NAD+ reserves rapidly, compounding tissue injury through loss of mitochondrial function and sirtuin activity ^[1][3]. Research published in Biogerontology summarised evidence that restoring NAD+ using precursor intermediates may be a valuable strategy for recovery from ischemic injury, in addition to age-associated defects ^[1]. In cardiac models, instability in NAD+ metabolism due to mtDNA damage has been directly linked to impaired mitochondrial function and cardiac communication through reduced NAD+-dependent SIRT3 activation ^[3]. These findings have motivated clinical interest in NAD+ precursors as potential adjuncts in ischemic conditions, though human trial data remain sparse.

How it is thought to work

NAD+ operates through two broad and interconnected roles inside the cell. As a redox coenzyme, it shuttles electrons between metabolic reactions: in glycolysis and the Krebs cycle, NAD+ accepts electrons (becoming NADH), and NADH then donates those electrons to the mitochondrial electron transport chain, driving ATP synthesis—the cell's primary energy currency ^[1][2]. This NAD+/NADH ratio is essential for maintaining cellular redox homeostasis; when the ratio falls, energy production falters and metabolic pathways stall ^[1]. NAD+ is synthesised in the body via three overlapping routes: de novo synthesis from tryptophan through the kynurenine pathway; the Preiss-Handler pathway from niacin; and the salvage pathway, which recycles nicotinamide (NAM) back into NAD+. The salvage pathway is dominant in most mammalian tissues, and its rate-limiting enzyme, NAMPT, declines in activity with age, which is a primary reason NAD+ levels fall as organisms grow older ^[2][4].

Beyond energy transfer, NAD+ acts as an indispensable substrate consumed by two major families of signalling enzymes. Sirtuins (SIRT1–7) are NAD+-dependent protein deacetylases that regulate stress responses, inflammation, mitochondrial biogenesis, and lifespan-related pathways; without adequate NAD+, their activity is severely curtailed ^[1][3]. PARP enzymes (principally PARP-1) detect DNA strand breaks and use NAD+ to construct poly(ADP-ribose) signalling chains on chromatin, enabling the recruitment of DNA repair proteins. Critically, prolonged or excessive PARP activation—such as occurs during oxidative stress—can deplete the entire cellular NAD+ pool, causing sirtuin shutdown and, ultimately, cell death by necrosis ^[3][5]. This NAD+-PARP-sirtuin triangle is central to current models explaining why NAD+ decline accelerates cellular aging and disease: as NAD+ falls, both protective genome maintenance (PARP) and metabolic longevity signalling (sirtuins) are simultaneously impaired ^[2][5].

Where the evidence stands

The preclinical evidence base for NAD+ is substantial. In rodent models, NAD+ augmentation through precursors such as NMN and NR is reliably associated with improvements in metabolic health, mitochondrial function, neurodegeneration markers, vascular function, and muscle insulin sensitivity across a wide variety of disease models ^[6][4]. In specific models of DNA repair disorders (XPA, CSB, Ataxia-Telangiectasia), NAD+ precursor supplementation decreased endogenous DNA damage accumulation and improved repair capacity ^[5]. Cardiac preclinical models show that NAD+ replenishment extends healthspan, prevents metabolic syndrome, reduces blood pressure, and improves multiple forms of cardiomyopathy ^[8]. These reproducible animal findings have fuelled optimism but the translation to humans has proven more difficult to establish.

As of 2025–2026, approximately 33 human intervention studies have been completed or are ongoing, of which 28 were randomised ^[6]. The consistent finding in human trials is that oral NAD+ precursors (NR, NMN) reliably and substantially increase circulating NAD+ levels ^[7][12]. However, the expected downstream improvements in functional health outcomes—cognition, vascular function, muscle performance, and body composition—have been far less consistently demonstrated ^[7]. A 2025 review in Nature Metabolism noted that evidence for an age-related decline in NAD+ levels in humans has been consistently observed only in a limited number of studies, and called for larger, randomised trials with validated disease-specific endpoints ^[7]. One notable exception is the finding that NMN improved muscle insulin sensitivity in prediabetic women in a Science-published trial ^[8]. Key limitations pervading the field include small sample sizes, short study durations, heterogeneous endpoints, and a lack of head-to-head comparisons between different NAD+ precursors ^[6][7]. The field is regarded as promising but not yet conclusive for most human indications.

Frequently asked questions

What is NAD+ and why is it important?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It is essential for converting nutrients into cellular energy (ATP), regulating DNA repair through PARP enzymes, and controlling aging-related signalling pathways through sirtuins. Without adequate NAD+, these fundamental cellular processes are impaired.

Does NAD+ really decline with age?

A large body of preclinical evidence shows that NAD+ levels fall across multiple tissues in aging animals. In humans, several studies report an age-related decline in blood NAD+ levels, though a 2025 Nature Metabolism review noted this has been consistently demonstrated in only a limited number of human studies. Research is ongoing to clarify the magnitude and tissue specificity of this decline in humans.

What is the difference between NAD+, NMN, and NR?

NAD+ is the active coenzyme itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursor molecules that the body converts into NAD+ through the salvage biosynthetic pathway. Because NAD+ itself is broken down during digestion, research has largely focused on these precursors as a means of raising intracellular NAD+ levels. Both NMN and NR have been shown in human trials to significantly increase blood NAD+ concentrations.

Can NAD+ or its precursors improve cognitive function?

Preclinical studies in mouse models of Alzheimer's disease and aging show consistent improvements in neuronal health and memory when NAD+ is restored. In humans, early trials show that NR can raise NAD+ in the brain and reduce some biomarkers linked to neurodegeneration, but no study to date has demonstrated a statistically significant improvement in cognitive test scores in healthy or mildly impaired adults. This remains an active and unresolved research question.

How does NAD+ support DNA repair?

When DNA is damaged—by UV radiation, oxidative stress, or other insults—PARP-1 enzymes are activated. PARPs consume NAD+ to build poly(ADP-ribose) signalling chains that recruit DNA repair proteins to the damage site. Adequate NAD+ levels are therefore a prerequisite for efficient DNA repair; when NAD+ is depleted, PARP activity stalls, allowing damage to accumulate and potentially trigger cell death.

What are sirtuins and how do they relate to NAD+?

Sirtuins (SIRT1–7) are a family of NAD+-dependent enzymes that remove acetyl groups from proteins, regulating a broad range of biological processes including mitochondrial function, inflammation, stress resistance, and genome maintenance. Because sirtuins strictly require NAD+ as a co-substrate, their activity is directly tied to the availability of NAD+ in the cell. Declining NAD+ with age therefore silences sirtuin pathways that would otherwise protect against aging-related cellular damage.

Is NAD+ research supported by human clinical trials?

Yes, though the field is still maturing. A 2026 systematic review identified 33 human intervention studies, of which 28 were randomised. Human trials consistently show that NAD+ precursors raise blood NAD+ levels reliably. Functional benefits—such as improved insulin sensitivity in prediabetic women—have been reported in some trials, but improvements in cognition, cardiovascular function, and muscle performance have not yet been consistently demonstrated across studies.

Are there any gaps or limitations in the current NAD+ research?

Major gaps include small sample sizes, short study durations (often 4–12 weeks), heterogeneous outcome measures, and a near-total absence of head-to-head comparisons between different NAD+ precursors. Human evidence for age-related NAD+ decline is less robust than animal data. Researchers and reviewers have called for large, randomised trials with validated, disease-specific, patient-important endpoints before clinical recommendations can be made.

Is NAD+ the same as vitamin B3 or niacin?

They are closely related but not identical. Niacin (nicotinic acid) and nicotinamide are both forms of vitamin B3, and both can serve as dietary precursors that the body uses to synthesise NAD+ through different biosynthetic pathways. NAD+ itself is the fully assembled, active coenzyme. A deficiency of niacin—and by extension, severely depleted NAD+—was historically responsible for the disease pellagra.

What is the role of NAD+ in cardiovascular health?

NAD+ is a critical regulator of cardiac energy production, mitochondrial function, and DNA repair in heart muscle cells. Research shows that NAD+ levels decline with aging, obesity, and hypertension—all major cardiovascular risk factors—and that low cardiac NAD+ is linked to mitochondrial dysfunction and increased oxidative stress. In animal models, restoring NAD+ has been shown to improve multiple forms of cardiomyopathy and reduce blood pressure, though large-scale human cardiovascular trials are still in early phases.

Glossary

NAD+ (Nicotinamide Adenine Dinucleotide)

A dinucleotide coenzyme present in all living cells that carries electrons in redox reactions and serves as a substrate for PARP and sirtuin enzymes central to energy metabolism, DNA repair, and aging.

Sirtuin

A family of seven NAD+-dependent protein deacetylase enzymes (SIRT1–7) that regulate metabolism, stress resistance, genome maintenance, and lifespan-related pathways.

PARP (Poly(ADP-Ribose) Polymerase)

A family of DNA repair enzymes—particularly PARP-1—that consume NAD+ to attach poly(ADP-ribose) chains to chromatin proteins, signalling the recruitment of DNA repair machinery to sites of strand breaks.

NAMPT (Nicotinamide Phosphoribosyltransferase)

The rate-limiting enzyme of the NAD+ salvage pathway in most mammalian tissues; its declining activity with age is a principal driver of falling cellular NAD+ levels.

Salvage pathway

The dominant biosynthetic route for NAD+ in mammals, which recycles the breakdown product nicotinamide back into NAD+ through sequential enzymatic steps, the first and rate-limiting of which is catalysed by NAMPT.

NMN (Nicotinamide Mononucleotide)

A direct biosynthetic precursor to NAD+ that enters the salvage pathway one step upstream of NAD+ synthesis via the enzyme NMNAT; studied in human trials as a means of raising intracellular NAD+ levels.

NR (Nicotinamide Riboside)

A form of vitamin B3 and an NAD+ precursor that enters the salvage pathway via nicotinamide riboside kinase (NRK), bypassing the rate-limiting NAMPT step; shown in human trials to reliably increase blood NAD+ concentrations.

Redox homeostasis

The cellular balance between oxidised (NAD+) and reduced (NADH) forms of the coenzyme, which is essential for sustaining energy-producing metabolic reactions and preventing oxidative damage.

References

1. Nicotinamide adenine dinucleotide emerges as a therapeutic target in aging and ischemic conditions — Biogerontology (2019)
2. NAD+ biosynthesis, aging, and disease — F1000Research / PMC (2018)
3. Instability in NAD+ metabolism leads to impaired cardiac mitochondrial function and communication — eLife / PMC (2021)
4. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns — PMC / Endocrine Reviews (2025)
5. Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity — Scientific Reports / PMC (2020)
6. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence — Ageing Research Reviews (2026)
7. NAD+ precursor supplementation in human ageing: clinical evidence and challenges — Nature Metabolism (2025)
8. NAD+ Metabolism in Cardiac Health, Aging, and Disease — Circulation / AHA Journals (2021)
9. NAD+ metabolism and therapeutic strategies in cardiovascular diseases — PMC / Redox Biology (2024)
10. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial — eClinicalMedicine / The Lancet (2025)
11. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach — PubMed / Journal of Alzheimer's Disease (2024)
12. NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis — Experimental Gerontology (2020)